Implantica (IMP) Q4 2024 earnings summary

Executive summary

• RefluxStop is nearing FDA approval with positive feedback on clinical modules and U.S. market entry preparations underway.

• Over 1,000 surgeries performed and more than 40 hospitals in Europe using the device, with 15 new hospitals added this year.

• RefluxStop demonstrates outstanding long-term clinical results, with only one patient requiring medication five years post-treatment.

• Largest real-world study in Germany showed 100% median improvement in GERD-HRQL.

• U.S. launch preparations include training centers and engagement with key payers and hospitals.

Financial highlights

• Q4 revenues/net sales decreased to EUR 442,000 (down 13–30% year-over-year) due to increased free devices for studies.

• Full year net sales rose 38% to EUR 1.94 million.

• Adjusted Q4 gross margin was 90%, down from 92% last year; full year gross margin at 92%, down from 94%.

• Q4 operating loss was EUR 7.17 million, up 3% year-over-year; full year operating loss increased 17% to EUR 25.47 million, mainly due to non-cash impairment and higher R&D expenses.

• End-2024 cash and equivalents stood at EUR 64.6 million, with no interest-bearing debt and a 96% equity ratio.

Outlook and guidance

• Business expected to continue growing, with substantial revenue opportunity dependent on U.S. approval or broad European reimbursement.

• Gross margin expected to remain high, with fluctuations due to subscale operations and free device programs.

• Final Module 3 submission for FDA approval is near completion, supporting US market entry.

• Pre-launch preparations for US market are progressing rapidly.

• Potential for capital raise to accelerate U.S. launch is under consideration.